Pharmaceuticals, Biotechnology & Life Sciences

Insider trading at Zai Lab shows CEO Du Ying’s liquidity‑managing buy‑sell‑buy cycle, with short‑term gains yet strong long‑term confidence in the biotech’s pipeline.

CEO Michael Egholm’s zero‑cost RSU purchases show strong insider confidence in Standard BioTools, signaling a long‑term growth bet and a potential catalyst for investor interest.

Insightful insider sales at Zai Lab reveal a tax‑covering move, not a distress signal, amid a 38% stock surge and biotech pipeline excitement.

Corcept insider buys reveal executive confidence amid legal risk, showing disciplined buying and long‑term optimism for investors.

Insider buying and selling at PTC shows exec confidence: Boulding’s $39.42 purchase amid $70 sales signals long‑term upside for the biotech.

Insider selling spurs investor curiosity: CFO trades 48,028 shares of Recursion amid 248 % buzz, balancing liquidity and long‑term AI‑drug potential.

Insider activity at Charles River Laboratories shows CFO holding no shares and CEO buying, signaling cautious optimism amid stable stock and growing contract buzz.

Insightful analysis of Avalo Therapeutics’ latest insider trade, revealing why the CEO’s purchase signals confidence amid volatility and future pipeline prospects.

Insmed CEO Lewis William’s latest insider trades show a strategic re‑balance at a deep discount, signalling confidence in the company’s long‑term biopharma prospects.

CEO Martine Rothblatt’s 10b5‑1 option sales signal a planned, long‑term exit at United Therapeutics, reflecting confidence in the company’s growth prospects.